User login
Key clinical point: In patients with human epidermal growth factor receptor 2-positive (ERBB2+, aka HER2+) metastatic breast cancer (BC), anti-ERBB2 treatment without vs with chemotherapy worsened the progression-free survival (PFS) rate but did not yield detrimental overall survival (OS) outcomes.
Major finding: Patients who did not receive vs received chemotherapy showed comparable OS rates at 2 years (79.0%; 90% CI 71.4%-85.4% vs 78.1%; 90% CI 70.4%-84.5%) but had shorter median PFS (8.4 months; 95% CI 7.9-12.0 vs 23.3 months; 95% CI 18.9-33.1).
Study details: This secondary analysis of a phase 2 trial included 210 patients with ERBB2+ metastatic BC who were randomly assigned to receive pertuzumab + trastuzumab with or without chemotherapy followed by trastuzumab-emtansine as the second-line therapy in both groups.
Disclosures: This study was supported by F. Hoffmann-La Roche AG and other sources. B Thürlimann declared owning stocks from F. Hoffmann-La Roche AG and some other authors declared ties with various sources, including F. Hoffmann-La Roche AG.
Source: Huober J et al for the Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab plus trastuzumab with or without chemotherapy followed by emtansine in ERBB2-positive metastatic breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 2023 (Aug 10). doi: 10.1001/jamaoncol.2023.2909
Key clinical point: In patients with human epidermal growth factor receptor 2-positive (ERBB2+, aka HER2+) metastatic breast cancer (BC), anti-ERBB2 treatment without vs with chemotherapy worsened the progression-free survival (PFS) rate but did not yield detrimental overall survival (OS) outcomes.
Major finding: Patients who did not receive vs received chemotherapy showed comparable OS rates at 2 years (79.0%; 90% CI 71.4%-85.4% vs 78.1%; 90% CI 70.4%-84.5%) but had shorter median PFS (8.4 months; 95% CI 7.9-12.0 vs 23.3 months; 95% CI 18.9-33.1).
Study details: This secondary analysis of a phase 2 trial included 210 patients with ERBB2+ metastatic BC who were randomly assigned to receive pertuzumab + trastuzumab with or without chemotherapy followed by trastuzumab-emtansine as the second-line therapy in both groups.
Disclosures: This study was supported by F. Hoffmann-La Roche AG and other sources. B Thürlimann declared owning stocks from F. Hoffmann-La Roche AG and some other authors declared ties with various sources, including F. Hoffmann-La Roche AG.
Source: Huober J et al for the Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab plus trastuzumab with or without chemotherapy followed by emtansine in ERBB2-positive metastatic breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 2023 (Aug 10). doi: 10.1001/jamaoncol.2023.2909
Key clinical point: In patients with human epidermal growth factor receptor 2-positive (ERBB2+, aka HER2+) metastatic breast cancer (BC), anti-ERBB2 treatment without vs with chemotherapy worsened the progression-free survival (PFS) rate but did not yield detrimental overall survival (OS) outcomes.
Major finding: Patients who did not receive vs received chemotherapy showed comparable OS rates at 2 years (79.0%; 90% CI 71.4%-85.4% vs 78.1%; 90% CI 70.4%-84.5%) but had shorter median PFS (8.4 months; 95% CI 7.9-12.0 vs 23.3 months; 95% CI 18.9-33.1).
Study details: This secondary analysis of a phase 2 trial included 210 patients with ERBB2+ metastatic BC who were randomly assigned to receive pertuzumab + trastuzumab with or without chemotherapy followed by trastuzumab-emtansine as the second-line therapy in both groups.
Disclosures: This study was supported by F. Hoffmann-La Roche AG and other sources. B Thürlimann declared owning stocks from F. Hoffmann-La Roche AG and some other authors declared ties with various sources, including F. Hoffmann-La Roche AG.
Source: Huober J et al for the Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab plus trastuzumab with or without chemotherapy followed by emtansine in ERBB2-positive metastatic breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol. 2023 (Aug 10). doi: 10.1001/jamaoncol.2023.2909